Abstract 7P
Background
Claudin-18.2 (CLDN18.2) the dominant isoform of CLDN18 in gastric tissue is a highly specific tight junction protein of the gastric mucosa expressed in gastric cancer & has emerged as a promising drug target. Zolbetuximab, a monoclonal antibody (Ab) targeting CLDN18.2 is reported to improve progression free & overall survival in combination with chemotherapy in the first-line treatment of CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric (G) & gastroesophageal junction (GEJ) cancers in 2 randomized phase 3 studies. Both studies (SPOTLIGHT, GLOW) met their primary endpoints. Patient selection for CLDN18.2 in these studies used the Ventana CLDN18 (43-14A) assay. It is important in the clinical setting to ensure accurate & reproducible results in the diagnosis of G/GEJ cancer for treatment options. This global ring study was conducted to assess analytical reproducibility & concordance of this assay with 2 other CLDN18 Abs (LSBio LS–B16145-100 & Novus Biologicals NBP2-32002) stained on 3 platforms to confirm possible diagnostic testing methods.
Methods
Tissue microarray (TMA) of 15 gastric cancer samples in triplicate cores was provided to 27 labs across 11 countries. Each lab stained the TMAs using 2-3 CLDN18 Abs with optimized protocols. The TMAs, also stained by the central lab, were used to achieve consensus by expert review. Using agreed scoring algorithms as per the phase 3 studies, IHC scores were generated per core & the results were collated for statistical analysis with the consensus results.
Results
Show high concordance among the 3 Abs across the assessed parameters when performed on each of the 3 platforms, with the highest accuracy & sensitivity observed for Ventana Ab & LSBio Ab across all 3 platforms. Table: 7P
Precision | Precision | Precision | Accuracy | Accuracy | Accuracy | Sensitivity | Sensitivity | Sensitivity | Specificity | Specificity | Specificity | |
Antibody | Ventana | Novus | LSBio | Ventana | Novus | LSBio | Ventana | Novus | LSBio | Ventana | Novus | LSBio |
Platform | ||||||||||||
Ventana | 0.96 | 0.88 | 0.94 | 0.95 | 0.88 | 0.88 | 0.93 | 0.67 | 0.85 | 0.97 | 0.96 | 0.92 |
Dako | - | 0.94 | 0.93 | - | 0.83 | 0.94 | - | 0.72 | 0.96 | - | 0.95 | 0.93 |
Leica | - | 0.79 | 0.97 | - | 0.94 | 0.93 | - | 0.89 | 0.91 | - | 0.95 | 0.96 |
Conclusions
The study shows multiple Abs applied on multiple platforms give highly reproducible and comparable results for detecting CLDN18.2 in gastric cancer providing a potential for their global adoption for CLDN18 testing.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Diaceutics PLC.
Funding
Astellas Pharma.
Disclosure
B. Jasani, A. Dodson, S. Parry, N. Atkey, P. Taniere: Non-Financial Interests, Institutional, Advisory Role, Performing consulting work on behalf of Astellas Pharma in regards to abstract being submitted’: Astellas Pharma. H. Schildhaus: Financial Interests, Institutional, Advisory Board: MSD, BMS, Novartis; Financial Interests, Institutional, Invited Speaker: AstraZeneca, Roche, Takeda, Agilent, ZytoVision; Financial Interests, Personal, Full or part-time Employment: Targos/DLS Inc.; Financial Interests, Institutional, Research Grant: Novartis; Financial Interests, Institutional, Funding: Blueprint medicines; Other, Personal, Other, Member of the QuIP Board (Quality Assurance Organisation): QuIP GmbH. S. Clare-Antony: Other, Institutional, Advisory Role, Performing consulting work on behalf of Astellas Pharma in regards to abstract being submitted: Astellas Pharma.
Resources from the same session
74P - Tumor agnostic comparison of immunohistochemistry and next-generation sequencing in detecting ALK fusions and assessment of ALK tyrosine kinase inhibitor efficacy
Presenter: Monica Chen
Session: Cocktail & Poster Display session
Resources:
Abstract
75P - Target identification by TIME phenotypes
Presenter: Robert Seitz
Session: Cocktail & Poster Display session
Resources:
Abstract
76P - Prediction of response to palliative chemotherapy by circulating tumor DNA (ctDNA) kinetics in metastatic pancreatic cancer
Presenter: Patrick Kirchweger
Session: Cocktail & Poster Display session
Resources:
Abstract
77P - Impact of germline HLA genotypes on clinical outcomes in patients (pts) with solid tumors treated with immunotherapy
Presenter: Katerin Rojas Laimito
Session: Cocktail & Poster Display session
Resources:
Abstract
78P - High resolution in situ analysis reveals phenotypic and functional diversification within single pancreatic tumour ducts
Presenter: Ellis Michiels
Session: Cocktail & Poster Display session
Resources:
Abstract
81P - Implementing genomic profiling as standard-of-care for glioblastoma patients
Presenter: Vincent Fougner
Session: Cocktail & Poster Display session
Resources:
Abstract
82P - Cyclic fasting-mimicking diet as a strategy to improve the efficacy of standard antitumor therapies in cancer patients
Presenter: Filippo Guglielmo Maria De Braud
Session: Cocktail & Poster Display session
Resources:
Abstract
83P - Evaluation of response-predictive biomarkers for lisavanbulin: A phase II study in patients with recurrent glioblastoma
Presenter: Juanita Lopez
Session: Cocktail & Poster Display session
Resources:
Abstract
84P - Racial disparities in phase I lung cancer clinical trials
Presenter: Rohit Singh
Session: Cocktail & Poster Display session
Resources:
Abstract
85P - Stereotactic radiotherapy improves disease control in oligoprogressive patients included in early clinical trials
Presenter: Antoine Mavrikios
Session: Cocktail & Poster Display session
Resources:
Abstract